Is This Cheap Cancer-Drug Company a Top Stock to Buy Now? [The Motley Fool]
TG Therapeutics, Inc. (TGTX)
Last tg therapeutics, inc. earnings: 11/12 07:34 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.tgtherapeutics.com
Company Research
Source: The Motley Fool
Zhiyuan Sun(TMFZhiyuanSun)Author BioZhiyuan Sun is a statistician with a knack for analyzing clinical trials and company financials. Investing in healthcare and cannabis is his passion, as well as looking out for new, actionable stock investment ideas in these sectors. Fool since April 00. Lives in Québec City, Canada.This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Question an investing thesis — even one of our own — helps us all think critically about investing and make decisions that helps us become smarter, happier, and richer.Follow @Bio_ChameleonOver the past year,TG TherapeuticsNASDAQ:TGTXiShares NASDAQ Biotechnology ETFNASDAQ:IBBAs it turns out, TG Therapeutics is still significantly undervalued, even after its 00 rally. Could larger companies be eyeing TG Therapeutics for its acquisition potential? Let's look at what the company has to offer in its efforts t
Show less
Read more
Impact Snapshot
Event Time:
TGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TGTX alerts
High impacting TG Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TGTX
News
- TG Therapeutics, Inc. (NASDAQ: TGTX) had its "buy" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $39.00 price target on the stock.MarketBeat
- TG Therapeutics, Inc. (NASDAQ: TGTX) had its "overweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $25.00 price target on the stock.MarketBeat
- TG Therapeutics, Inc. (NASDAQ: TGTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.MarketBeat
- TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual MeetingGlobeNewswire
- TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis [Yahoo! Finance]Yahoo! Finance
TGTX
Earnings
- 2/28/24 - Beat
TGTX
Sec Filings
- 4/18/24 - Form PRE
- 3/15/24 - Form 4
- 3/13/24 - Form 4
- TGTX's page on the SEC website